Marine Gasparian - Search Results

Year	Number of Results
2003	1
2007	1
2009	1
2010	1
2011	1
2012	1
2013	1
2014	1
2015	1
2020	2
2021	3
2022	5
2023	5
2024	2

1

Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway.

Yagolovich AV, Gasparian ME, Dolgikh DA. Yagolovich AV, et al. Among authors: gasparian me. Pharmaceutics. 2023 Feb 3;15(2):515. doi: 10.3390/pharmaceutics15020515. Pharmaceutics. 2023. PMID: 36839837 Free PMC article. Review.

2

DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma.

Yagolovich AV, Isakova AA, Artykov AA, Vorontsova YV, Mazur DV, Antipova NV, Pavlyukov MS, Shakhparonov MI, Gileva AM, Markvicheva EA, Plotnikova EA, Pankratov AA, Kirpichnikov MP, Gasparian ME, Dolgikh DA. Yagolovich AV, et al. Among authors: gasparian me. Int J Mol Sci. 2022 Oct 21;23(20):12687. doi: 10.3390/ijms232012687. Int J Mol Sci. 2022. PMID: 36293545 Free PMC article.

3

ONC201-Induced Mitochondrial Dysfunction, Senescence-like Phenotype, and Sensitization of Cultured BT474 Human Breast Cancer Cells to TRAIL.

Mishukov A, Odinokova I, Mndlyan E, Kobyakova M, Abdullaev S, Zhalimov V, Glukhova X, Galat V, Galat Y, Senotov A, Fadeev R, Artykov A, Gasparian ME, Solovieva M, Beletsky I, Holmuhamedov E. Mishukov A, et al. Among authors: gasparian me. Int J Mol Sci. 2022 Dec 8;23(24):15551. doi: 10.3390/ijms232415551. Int J Mol Sci. 2022. PMID: 36555190 Free PMC article.

4

Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor Specificity.

Yagolovich AV, Artykov AA, Isakova AA, Vorontsova YV, Dolgikh DA, Kirpichnikov MP, Gasparian ME. Yagolovich AV, et al. Among authors: gasparian me. Int J Mol Sci. 2022 May 24;23(11):5860. doi: 10.3390/ijms23115860. Int J Mol Sci. 2022. PMID: 35682540 Free PMC article.

5

Toxicity Evaluation and Controlled-Release of Curcumin-Loaded Amphiphilic Poly-N-vinylpyrrolidone Nanoparticles: In Vitro and In Vivo Models.

Luss AL, Bagrov DV, Yagolovich AV, Kukovyakina EV, Khan II, Pokrovsky VS, Shestovskaya MV, Gasparian ME, Dolgikh DA, Kuskov AN. Luss AL, et al. Among authors: gasparian me. Pharmaceutics. 2023 Dec 19;16(1):8. doi: 10.3390/pharmaceutics16010008. Pharmaceutics. 2023. PMID: 38276486 Free PMC article.

6

Amphiphilic Poly(N-vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells.

Yagolovich A, Kuskov A, Kulikov P, Kurbanova L, Bagrov D, Artykov A, Gasparian M, Sizova S, Oleinikov V, Gileva A, Kirpichnikov M, Dolgikh D, Markvicheva E. Yagolovich A, et al. Among authors: gasparian m. Pharmaceutics. 2021 Sep 7;13(9):1413. doi: 10.3390/pharmaceutics13091413. Pharmaceutics. 2021. PMID: 34575490 Free PMC article.

7

Corrigendum: Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL.

Artykov AA, Yagolovich AV, Dolgikh DA, Kirpichnikov MP, Trushina DB, Gasparian ME. Artykov AA, et al. Among authors: gasparian me. Front Cell Dev Biol. 2022 Feb 14;9:820069. doi: 10.3389/fcell.2021.820069. eCollection 2021. Front Cell Dev Biol. 2022. PMID: 35237612 Free PMC article.

8

Strategy for improvement of enteropeptidase efficiency in tag removal processes.

Gasparian ME, Bychkov ML, Dolgikh DA, Kirpichnikov MP. Gasparian ME, et al. Protein Expr Purif. 2011 Oct;79(2):191-6. doi: 10.1016/j.pep.2011.04.005. Epub 2011 Apr 15. Protein Expr Purif. 2011. PMID: 21515380

9

Doxorubicin-Loaded Polyelectrolyte Multilayer Capsules Modified with Antitumor DR5-Specific TRAIL Variant for Targeted Drug Delivery to Tumor Cells.

Gileva A, Trushina D, Yagolovich A, Gasparian M, Kurbanova L, Smirnov I, Burov S, Markvicheva E. Gileva A, et al. Among authors: gasparian m. Nanomaterials (Basel). 2023 Feb 27;13(5):902. doi: 10.3390/nano13050902. Nanomaterials (Basel). 2023. PMID: 36903780 Free PMC article.

10

Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL.

Artykov AA, Yagolovich AV, Dolgikh DA, Kirpichnikov MP, Trushina DB, Gasparian ME. Artykov AA, et al. Among authors: gasparian me. Front Cell Dev Biol. 2021 Sep 30;9:733688. doi: 10.3389/fcell.2021.733688. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34660590 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

23 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year